Literature DB >> 23963869

Effects of subclass change on the structural stability of chimeric, humanized, and human antibodies under thermal stress.

Takahiko Ito1, Kouhei Tsumoto.   

Abstract

To address how changes in the subclass of antibody molecules affect their thermodynamic stability, we prepared three types of four monoclonal antibody molecules (chimeric, humanized, and human) and analyzed their structural stability under thermal stress by using size-exclusion chromatography, differential scanning calorimetry (DSC), circular dichroism (CD), and differential scanning fluoroscopy (DSF) with SYPRO Orange as a dye probe. All four molecules showed the same trend in change of structural stability; the order of the total amount of aggregates was IgG1 < IgG2 < IgG4. We thus successfully cross-validated the effects of subclass change on the structural stability of antibodies under thermal stress by using four methods. The T(h) values obtained with DSF were well correlated with the onset temperatures obtained with DSC and CD, suggesting that structural perturbation of the CH2 region could be monitored by using DSF. Our results suggested that variable domains dominated changes in structural stability and that the physicochemical properties of the constant regions of IgG were not altered, regardless of the variable regions fused.
© 2013 The Protein Society.

Entities:  

Keywords:  antibody; circular dichroism; differential scanning calorimetry; differential scanning fluoroscopy; subclass change; thermodynamic stability

Mesh:

Substances:

Year:  2013        PMID: 23963869      PMCID: PMC3831669          DOI: 10.1002/pro.2340

Source DB:  PubMed          Journal:  Protein Sci        ISSN: 0961-8368            Impact factor:   6.725


  44 in total

1.  Acid-induced aggregation of human monoclonal IgG1 and IgG2: molecular mechanism and the effect of solution composition.

Authors:  Sanjay B Hari; Hollis Lau; Vladimir I Razinkov; Shuang Chen; Ramil F Latypov
Journal:  Biochemistry       Date:  2010-11-02       Impact factor: 3.162

2.  Influence of pH on heat-induced aggregation and degradation of therapeutic monoclonal antibodies.

Authors:  Tomoyoshi Ishikawa; Takahiko Ito; Ryosuke Endo; Keiko Nakagawa; Eiji Sawa; Kaori Wakamatsu
Journal:  Biol Pharm Bull       Date:  2010       Impact factor: 2.233

Review 3.  Strategies and challenges for the next generation of therapeutic antibodies.

Authors:  Alain Beck; Thierry Wurch; Christian Bailly; Nathalie Corvaia
Journal:  Nat Rev Immunol       Date:  2010-05       Impact factor: 53.106

4.  IgG2m4, an engineered antibody isotype with reduced Fc function.

Authors:  Zhiqiang An; Gail Forrest; Renee Moore; Michael Cukan; Peter Haytko; Lingyi Huang; Salvatore Vitelli; Jing Zhang Zhao; Ping Lu; Jin Hua; Christopher R Gibson; Barrett R Harvey; Donna Montgomery; Dennis Zaller; Fubao Wang; William Strohl
Journal:  MAbs       Date:  2009 Nov-Dec       Impact factor: 5.857

5.  Immunogenicity of aggregates of recombinant human growth hormone in mouse models.

Authors:  Amber Haynes Fradkin; John F Carpenter; Theodore W Randolph
Journal:  J Pharm Sci       Date:  2009-09       Impact factor: 3.534

6.  High throughput thermostability screening of monoclonal antibody formulations.

Authors:  Feng He; Sabine Hogan; Ramil F Latypov; Linda O Narhi; Vladimir I Razinkov
Journal:  J Pharm Sci       Date:  2010-04       Impact factor: 3.534

Review 7.  Advances in the assessment and control of the effector functions of therapeutic antibodies.

Authors:  Xu-Rong Jiang; An Song; Svetlana Bergelson; Thomas Arroll; Bhavin Parekh; Kimberly May; Shan Chung; Robert Strouse; Anthony Mire-Sluis; Mark Schenerman
Journal:  Nat Rev Drug Discov       Date:  2011-02       Impact factor: 84.694

8.  High-throughput measurement, correlation analysis, and machine-learning predictions for pH and thermal stabilities of Pfizer-generated antibodies.

Authors:  Amy C King; Matthew Woods; Wei Liu; Zhijian Lu; Davinder Gill; Mark R H Krebs
Journal:  Protein Sci       Date:  2011-07-13       Impact factor: 6.725

9.  Increased aggregation propensity of IgG2 subclass over IgG1: role of conformational changes and covalent character in isolated aggregates.

Authors:  Heather Franey; Stephen R Brych; Carl G Kolvenbach; Rahul S Rajan
Journal:  Protein Sci       Date:  2010-09       Impact factor: 6.725

Review 10.  Therapeutic antibodies for autoimmunity and inflammation.

Authors:  Andrew C Chan; Paul J Carter
Journal:  Nat Rev Immunol       Date:  2010-05       Impact factor: 53.106

View more
  21 in total

1.  Monoclonal Antibodies Follow Distinct Aggregation Pathways During Production-Relevant Acidic Incubation and Neutralization.

Authors:  Thomas Skamris; Xinsheng Tian; Matthias Thorolfsson; Hanne Sophie Karkov; Hanne B Rasmussen; Annette E Langkilde; Bente Vestergaard
Journal:  Pharm Res       Date:  2015-11-12       Impact factor: 4.200

Review 2.  Considerations for the Design of Antibody-Based Therapeutics.

Authors:  Dennis R Goulet; William M Atkins
Journal:  J Pharm Sci       Date:  2019-06-04       Impact factor: 3.534

3.  Protein aggregation and mitigation strategy in low pH viral inactivation for monoclonal antibody purification.

Authors:  Weixin Jin; Zizhuo Xing; Yuanli Song; Chao Huang; Xuankuo Xu; Sanchayita Ghose; Zheng Jian Li
Journal:  MAbs       Date:  2019-09-02       Impact factor: 5.857

4.  Engineering an IgG Scaffold Lacking Effector Function with Optimized Developability.

Authors:  Frederick W Jacobsen; Riki Stevenson; Cynthia Li; Hossein Salimi-Moosavi; Ling Liu; Jie Wen; Quanzhou Luo; Kristine Daris; Lynette Buck; Sterling Miller; Shu-Yin Ho; Wei Wang; Qing Chen; Kenneth Walker; Jette Wypych; Linda Narhi; Kannan Gunasekaran
Journal:  J Biol Chem       Date:  2016-12-19       Impact factor: 5.157

5.  Acid-induced aggregation propensity of nivolumab is dependent on the Fc.

Authors:  Boning Liu; Huaizu Guo; Jin Xu; Ting Qin; Lu Xu; Junjie Zhang; Qingcheng Guo; Dapeng Zhang; Weizhu Qian; Bohua Li; Jianxin Dai; Sheng Hou; Yajun Guo; Hao Wang
Journal:  MAbs       Date:  2016-06-16       Impact factor: 5.857

6.  Engineering a human IgG2 antibody stable at low pH.

Authors:  Seiji Saito; Hiroshi Namisaki; Keiko Hiraishi; Nobuaki Takahashi; Shigeru Iida
Journal:  Protein Sci       Date:  2020-03-18       Impact factor: 6.725

7.  Investigating Therapeutic Protein Structure with Diethylpyrocarbonate Labeling and Mass Spectrometry.

Authors:  Nicholas B Borotto; Yuping Zhou; Stephen R Hollingsworth; John E Hale; Eric M Graban; Robert C Vaughan; Richard W Vachet
Journal:  Anal Chem       Date:  2015-10-01       Impact factor: 6.986

Review 8.  Heat denaturation of the antibody, a multi-domain protein.

Authors:  Yoko Akazawa-Ogawa; Hidenori Nagai; Yoshihisa Hagihara
Journal:  Biophys Rev       Date:  2017-12-18

9.  Signature of Antibody Domain Exchange by Native Mass Spectrometry and Collision-Induced Unfolding.

Authors:  Yasunori Watanabe; Snezana Vasiljevic; Joel D Allen; Gemma E Seabright; Helen M E Duyvesteyn; Katie J Doores; Max Crispin; Weston B Struwe
Journal:  Anal Chem       Date:  2018-05-25       Impact factor: 6.986

10.  Stabilizing the CH2 Domain of an Antibody by Engineering in an Enhanced Aromatic Sequon.

Authors:  Wentao Chen; Leopold Kong; Stephen Connelly; Julia M Dendle; Yu Liu; Ian A Wilson; Evan T Powers; Jeffery W Kelly
Journal:  ACS Chem Biol       Date:  2016-04-29       Impact factor: 5.100

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.